The HemOnc Pulse

Krish Patel, MD, Talks Glofitamab, Other Novel Therapies in DLBCL

Dr. Patel, of the Swedish Cancer Institute in Seattle, Washington, joins Chadi Nabhan, MD, MBA, FACP, on “The HemOnc Pulse” to discuss novel frontline therapies in the lymphoma space, including the bispecific antibody glofitamab.
They also discuss bispecifics versus chimeric antigen receptor (CAR) T-cell therapy, fixed duration therapy and step-up dosing, and how to sequence therapy.

Aaron Goodman, MD, Tells Us the 'Crux' of Castleman Disease

In this episode of "The HemOnc Pulse," Dr. Goodman, an Associate Professor of Medicine at the University of California San Diego, joins Chadi Nabhan, MD, MBA, FACP, to discuss Castleman Disease.
Dr. Goodman explains why the rare disease is often mismanaged, how each subtype is diagnosed and treated, and how it's comparable to hematologic cancers like lymphoma or myeloma.

Is MRD Negativity the New Benchmark in ALL Treatment Strategies?

Elias Jabbour, MD, an Executive Editor of Blood Cancers Today and a Professor of Leukemia at the University of Texas MD Anderson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to discuss the function of measurable residual disease in treating acute lymphocytic leukemia (ALL) and other progress that has been made in treating patients with Philadelphia chromosome-positive and Philadelphia chromosome-negative ALL. 
Dr. Jabbour also provides a brief historical perspective on tyrosine kinase inhibitors (TKIs), explaining how the therapies have improved survival outcomes in Ph+ ALL with or without transplantation. 

Part Two: Drs. Dahiya, Spiegel Return to Discuss 'Black Box' Warning on CAR-T Therapies

Saurabh Dahiya, MD, FACP, of Stanford Medicine, and Jay Spiegel, MD, of the University of Miami, join The HemOnc Pulse for the second half of a two-part series on reports regarding secondary T-cell malignancies in patients after being treated with a chimeric antigen receptor (CAR) T-cell therapy and updates from the US Food and Drug Administration (FDA) on the issue.
Drs. Dahiya and Spiegel return to the show shortly following the announcement that the FDA sent requests to drug manufacturers on January 9 to update prescription labels with "Black Box" warnings on the six CAR-T therapies used to treat blood cancers.
Part one of the series covers the FDA's initial report in November 2023 and why it set off a "firestorm" in the hematology-oncology community. 

Dr. Coombs Spotlights Recent CHIP Updates

In this season's fourth episode of "The HemOnc Pulse," Catherine Coombs, MD, an Associate Professor in the Division of Hematology/Oncology at the University of California, Irvine, School of Medicine, highlights recent studies in clonal hematopoiesis of indeterminate potential (CHIP) presented at the 65th American Society of Hematology Meeting & Exposition.
Dr. Coombs discusses research on reversing the adverse effects of CHIP, particularly its association with atherosclerotic cardiovascular disease, using interventions such as selective nuclear export inhibitors. She also illustrates another study that looks at the prevalence of CHIP in patients undergoing autologous hematopoietic stem cell transplant in lymphoma, which showed an increased risk of cardiovascular disease and lower survival rates.
 

Drs. Dahiya, Spiegel Discuss CAR-T Secondary Malignancies Risk

An all-new episode of The HemOnc Pulse with Saurabh Dahiya, MD, FACP, of Stanford Medicine, and Jay Spiegel, MD, of the University of Miami, features a discussion on the link between chimeric antigen receptor (CAR)-T cell therapies and secondary T-cell malignancies. The episode follows on the heels of the US Food and Drug Administration's request to drug manufacturers of the six CAR-T therapies to make safety-related labeling changes.
 
 
 
 

Aditi Shastri, MD: Clinicians Need to ‘Come Together’ on TP53-Mutated MDS

This episode features a conversation between Dr. Shastri, an Assistant Professor of Medicine at the Montefiore Einstein Comprehensive Cancer Center in the Bronx, New York, and The HemOnc Pulse host, Chadi Nabhan; MD; MBA; FACP; on the latest news in myelodysplastic syndromes (MDS), including the final readout from the COMMANDS trial and the clinical implications of TP53-mutated MDS.

What It Takes to Harmonize the World’s Hodgkin Lymphoma Data

The first episode of The HemOnc Pulse of the new year features an in-depth discussion by the leading researchers of the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) consortium.
Principal investigators Susan Parsons, MD, MRP; and Andrew Evans, DO, MBA, MSc; are joined by Matthew Maurer, DMSc; to share the story behind harmonizing the world's Hodgkin lymphoma data, and what the effort means for both clinicians and patients.

Dr. Usmani Discusses Perseus, IsKia, Data Plus More Myeloma Updates

Saad Usmani, MD, MBA, FACP, Chief of the Myeloma Service at the Memorial Sloan Kettering Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, on The HemOnc Pulse to chat about the latest research in multiple myeloma from the 65th American Society of Hematology (ASH) Annual Meeting and Exposition.
Dr. Usmani shares insights on the evolution in myeloma treatment since he first started practicing in the hematologic oncology space. He also reflects on the Perseus and IsKia trials, which were presented at ASH 2023.

Dr. Venugopal Offers Her Thoughts on the Latest MDS News

Sangeetha Venugopal, MD, of the University of Miami Sylvester Comprehensive Cancer Center, offers her thoughts on the investigational drug KER-050 in lower-risk myelodysplastic syndromes (MDS), the COMMANDS trial, and if she believes MDS is a distinct disease.
She also highlights the latest research in MDS at the 65th American Society of Hematology Annual Meeting and Exposition.